An Efficacy and Safety Study of GNR-068 (Ustekinumab Biosimilar) and Stelara® in the Treatment of Patients With Moderate to Severe Plaque Psoriasis

NCT06488664 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

422

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

BIOLOGICAL: GNR-068
BIOLOGICAL: Stelara®

Sponsor

AO GENERIUM